Aug 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) receives "Notice of Allowance" regarding granting of a patent in the United States.

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs using the company's unique technology platform, announces that the company has received a so-called "Notice of Allowance" from the US Patent Office (USPTO).

The patent, which extends and complements QuiaPEG's patent portfolio, and which primarily concerns permanent PEGylation technology, will provide patent protection to 2034.

QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message